The landscape of myasthenia gravis treatment has evolved significantly with the introduction of advanced therapies such as complement inhibitors and FcRn modulators. These novel treatments offer targeted immunosuppression, improved disease control, and the potential for steroid-sparing strategies, thereby enhanc...
Robert Lisak has made important contributions to our understanding of the pathophysiology and therapy of myasthenia gravis. This review will touch upon some of his work as it discusses current therapies and the potential for new treatments based on the evolving knowledge of the underlying basis of ...
This article presents a summary of the new medications approved for generalized myasthenia gravis (gMG) since 2017. Pivotal clinical trials that led to the
Spotlight On: Myasthenia Gravis Myasthenia gravis issues: health disparities, quality of life, stigma, gender issues, and treatment access. My Experience If you have MG, don’t be afraid to get tools that’ll help you get through your day. –Alexandria EvansDiagnosed with MG My Experience If...
Myasthenia gravis (MG) is an autoimmune disease caused by antibodies against the acetylcholine receptor (AChR), muscle-specific kinase (MuSK) or other AChR-related proteins in the postsynaptic muscle membrane. Localized or general muscle weakness is the predominant symptom and is induced by the antib...
Panelists discuss how recent data presented at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) conference may impact clinical practice for myasthenia gravis, highlighting emerging treatments they find particularly promising for future management of the condition. ...
There is no cure for myasthenia gravis, but treatments are available that can help keep symptoms under control. These may include medications, surgery, lifestyle changes, and other procedures.In some people, MG may go into remission, allowing patients to discontinue treatment or lower the dose ...
Myasthenia gravis (MG) is estimated to affect as many as 60,000 patients in the United States and more than 700,000 people worldwide. In approximately 10% of patients, complications can be life-threatening. However, with the right treatment, MG can be a manageable disease, and patients can...
We performed ten plasma perfusion (PP) treatments on eight patients affected by Myasthenia Gravis (MG) with high serum levels of autoantibodies against acetylcholine receptors (anti AChR-AB), and one PP treatment on a patient with MG of probable genetic origin and without specific antibodies. All...
Efgartigimod is an antibody fragment designed to reduce pathogenic IgG antibodies and block the IgG recycling process in patients with generalized myasthenia gravis.